When examining the impact of PECAM1 expression on the overall survival rate in NSCLC subtypes, we observed a dichotomy: high PECAM1 expression was linked to longer overall survival and a lower HR (HR = 0.64) in LUAD patients, whereas in LUSC patients, elevated PECAM1 levels were associated with shorter overall survival and an increased HR (HR = 1.4) (Figure 9B,C). The gene discussed is PECAM1; the disease is non-small cell lung carcinoma.